Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;39(4):961-970.
doi: 10.1007/s10637-021-01079-5. Epub 2021 Feb 10.

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL

Linlin Zhao #  1 , Chengfang Lv #  2 , Lili Sun  3 , Qi Li  3 , Yuhuang Wang  3 , Min Wu  3 , Yuying Wang  3 , Zhibo Guo  3 , Sicheng Bian  3 , Desheng Kong  4 , Leilei Lin  3 , Yu Wang  3 , Jin Zhou  5 , Yinghua Li  6
Affiliations

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL

Linlin Zhao et al. Invest New Drugs. 2021 Aug.

Abstract

Our previous studies revealed that MYCN downregulates the expression of DKK3, activates the Wnt/β-catenin signalling pathway at the transcriptional level, and thereby promotes the development of B cell acute lymphocytic leukaemia (B-ALL) but does not affect the methylation of the DKK3 promoter. Some studies have shown that MYCN is associated with histone acetylation. We speculate that histone deacetylase inhibitors (HDACis) can inhibit the Wnt/β-catenin signalling pathway by inhibiting MYCN and increasing the expression of DKK3. Based on previous experiments, we tested this hypothesis by analysing the changes in MYCN, DKK3 and the Wnt/β-catenin signalling pathways in B-ALL cells after treatment with the selective HDACi chidamide. The in vitro and in vivo experiments confirmed that chidamide inhibited the expression of MYCN and increased the expression of DKK3 by inhibiting the activity of histone deacetylase, and these effects resulted in inhibition of the Wnt/β-catenin signalling pathway and the proliferation of B-ALL cells. These findings indicate that chidamide might be used alone or in combination with other chemotherapy regimens for patients with B-ALL and thus provide a new approach to the treatment of B-ALL.

Keywords: B cell acute lymphocytic leukaemia; Chidamide; DKK3; MYCN; Wnt/β-catenin.

PubMed Disclaimer

References

    1. Malouf C, Ottersbach K (2017) Molecular processes involved in B cell acute lymphoblastic leukaemia. Cell Mol Life Sci 75:417–446. https://doi.org/10.1007/s00018-017-2620-z - DOI - PubMed - PMC
    1. Ciprian T, Shigeo F, Cristian B, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S (2018) Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia. Front Immunol 9:239–251. https://doi.org/10.3389/fimmu.2018.00239 - DOI
    1. Paul S, Kantarjian H, Jabbour EJ (2016) Adult acute lymphoblastic leukemia. Mayo Clin Proc 91:1645–1666. https://doi.org/10.1016/j.mayocp.2016.09.010 - DOI - PubMed
    1. Ustwani OA, Gupta N, Bakhribah H, Griffiths EA, Wang ES, Wetzler M (2015) Clinical updates in adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol 99:189–199. https://doi.org/10.1016/j.critrevonc.2015.12.007 - DOI - PubMed
    1. Frey NV, Luger SM (2015) How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 126:589–596. https://doi.org/10.1182/blood-2014-09-551937 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources